PCSA
NSCProcessa Pharmaceuticals Inc.
Healthcare•Biotechnology
Watchlist:
Last updated: Friday 4th July 2025
0.19
+0.01 (3.34%)
Prev Close:0.1885
Open:0.19
Bid:0.1935
Ask:0.1957
52 Week Range
0.153.10
Volume:17,306,057
Mkt Cap:2 M
24
MarketXLS Rank ®
Weak Hold
Price Target
$0.22
+12.9%
Financials
Financial Statements
PCSA - Income Statement (Annual)
| Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Acquired In Process Rn D | 9 M | |||||||||
| Acquired In Process Rn D Income | -3 M | |||||||||
| Acquisition Expense | 42942.0 | |||||||||
| Depreciation And Amortization | -1865.0 | -1381.0 | -60251.0 | |||||||
| Diluted Discontinuous Operations | -0.21 | |||||||||
| Fees | 42942.0 | |||||||||
| Gain On Sale Of PPE | -25000.0 | -60743.0 | ||||||||
| Gains Loss On Disposal Of Discontinued Operations | 1197.0 | -371307.0 | ||||||||
| General And Administrative Expense | 5 M | 6 M | 9 M | 5 M | 3 M | 2 M | 1 M | -111799.0 | -32327.0 | -50035.0 |
| Gross Profit Margin (profit Margin After CGS) | 5000.0 | 131465.0 | ||||||||
| Impairment Of Capital Assets | 62554.0 | |||||||||
| Interest Expense Non Operating | 362.0 | 281122.0 | 36658.0 | 161205.0 | 59063.0 | 245384.0 | 235644.0 | |||
| Interest Expense Operating | -25356.0 | |||||||||
| Minority Interests | -43058.0 | -42942.0 | ||||||||
| Misc Other Special Charges | -391108.0 | 5181.0 | 4454.0 | 115159.0 | ||||||
| Net Income (loss) | -12 M | -11 M | -13 M | -11 M | -14 M | -3 M | -4 M | -2 M | -2 M | -9 M |
| Net Income Common Stockholders | -12 M | -11 M | -13 M | -11 M | -19 M | -3 M | -4 M | -2 M | -2 M | -9 M |
| Net Income Continuous Operations | -12 M | -11 M | -27 M | -11 M | -14 M | -3 M | -4 M | -2 M | -2 M | -9 M |
| Net Income Discontinuous Operations | 1197.0 | -371307.0 | ||||||||
| Net Non Operating Interest Income Expense | 201088.0 | 335541.0 | 101202.0 | 11627.0 | -277948.0 | -25110.0 | -142908.0 | -53882.0 | 4454.0 | -230993.0 |
| Normalized Income | -12 M | |||||||||
| Operating Income | -12 M | -11 M | -28 M | -12 M | -15 M | -4 M | -5 M | -2 M | -2 M | -4 M |
| Operating Income Before Depreciation (EBITDA) | -12 M | -11 M | -27 M | -11 M | -14 M | -3 M | -4 M | -2 M | -2 M | -8 M |
| Operating Expense | 12 M | 11 M | 20 M | 12 M | 15 M | 4 M | 5 M | 2 M | 2 M | 4 M |
| Other Gand A | 5 M | 6 M | 9 M | 5 M | 3 M | 2 M | 1 M | -111799.0 | -32327.0 | -50035.0 |
| Other Impairment Of Capital Assets | 7 M | -15330.0 | 2 M | |||||||
| Other Operating Expenses | 90000.0 | 97000.0 | 96785.0 | 94263.0 | 97545.0 | 2 M | 2 M | 3 M | ||
| Other Write Off | -5148.0 | |||||||||
| Promotion And Advertising | -135.0 | -3850.0 | -25431.0 | |||||||
| Rent And Landing Fees | -5535.0 | -2250.0 | -50035.0 | |||||||
| Research Expense | 7 M | 6 M | 11 M | 7 M | 12 M | 2 M | 3 M | 964164.0 | 6558.0 | 29246.0 |
| Restructring And Mn A Income | -2 M | -43058.0 | ||||||||
| Salaries And Wages | 629514.0 | 2 M | 9 M | 3 M | 3 M | -510478.0 | -74063.0 | -6691.0 | -425000.0 | |
| Selling And Marketing Expense | 1 M | 838269.0 | -3850.0 | 945460.0 | ||||||
| Selling Expense | 1 M | 838269.0 | 69968.0 | 945460.0 | ||||||
| Total Income Available For Interest Expense (EBIT) | -12 M | -11 M | -27 M | -12 M | -15 M | -4 M | -5 M | -2 M | -2 M | -8 M |
| Total Revenues | 10000.0 | 226850.0 | ||||||||
| Total Expenses | 12 M | 11 M | 20 M | 12 M | 15 M | 4 M | 5 M | 2 M | 2 M | 4 M |
| Total Revenue | 5000.0 | 269792.0 | ||||||||
| Amord | 788495.0 | 790488.0 | 795328.0 | -795328.0 | -621647.0 | -23370.0 | -967.0 | -178571.0 | ||
| Avgshs | 3 M | 1 M | 16 M | 765973.0 | 374983.0 | 6 M | 5 M | 5 M | 2 M | 2 M |
| Avgshsdt | 3 M | 1 M | 16 M | 765973.0 | 6 M | 5 M | 5 M | 2 M | 2 M | |
| Basiceps | -3.87 | -8.48 | -1.7 | -15.0 | -50.8 | -0.42 | ||||
| Basicepscont | -3.87 | -8.48 | -1.7 | -15.0 | -50.8 | |||||
| Cor | -5000.0 | 138327.0 | ||||||||
| Depamor | -1865.0 | -1381.0 | -60251.0 | |||||||
| Dileps | -3.87 | -8.48 | -1.7 | -15.0 | -50.8 | -0.7 | -0.7 | -0.42 | -0.21 | -2.38 |
| Dilepscont | -3.87 | -8.48 | -0.7 | -0.7 | -0.42 | -0.21 | -2.17 | |||
| Intinc | 201088.0 | 335541.0 | 101202.0 | 11627.0 | 3174.0 | 11548.0 | 18297.0 | 5181.0 | 4454.0 | 4651.0 |
| Netincdisc | -12 M | -11 M | -13 M | -11 M | -14 M | -3 M | -4 M | -2 M | -2 M | -9 M |
| Othincexp | 7 M | 391108.0 | -8 M | -20511.0 | -4454.0 | 4 M | ||||
| Othspecchg | 17 M | |||||||||
| Pretaxinc | -12 M | -11 M | -27 M | -12 M | -15 M | -4 M | -5 M | -2 M | -2 M | -9 M |
| Resdev | 7 M | 6 M | 11 M | 7 M | 12 M | 2 M | 3 M | 964164.0 | -2 M | 29246.0 |
| Restruct | -2 M | -43058.0 | ||||||||
| Sga | 5 M | 6 M | 9 M | 5 M | 3 M | 2 M | 1 M | 838269.0 | 69968.0 | 945460.0 |
| Shsout | 5 M | 3 M | 25 M | 792181.0 | 776080.0 | 5 M | 5 M | 5 M | 4 M | 4 M |
| Specincchg | -17 M | 9 M | 2 M | 43058.0 | -62554.0 | |||||
| Taxprov | -7 M | -530611.0 | -1 M | -602716.0 | -902801.0 | -100.0 |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.